Tmem185a, a gene with its specific functions yet to be fully elaborated in a comprehensive manner. Based on current knowledge, it may be involved in various biological processes as its copy number can be affected by genomic rearrangements, like in a case of a complex rearrangement causing severe hemophilia A where TMEM185A was duplicated along with other genes, though its biological effect in this context did not seem dosage-dependent [3].

In cancer research, TMEM185A was identified as one of the neoantigens specifically present in lymph-node-positive breast cancers, making it a potential target for vaccine design [1]. In urinary bladder cancer, it was part of a four-gene signature (along with TMPRSS11E, SCEL, KRT78) that could predict overall survival, and this four-gene risk score had potential clinical implications in selecting high-risk patients for aggressive therapy [2]. In stage III serous ovarian carcinoma, TMEM185A was among the down-regulated genes identified by an annealing control primer system, and these differentially expressed genes might help predict patient prognosis and suggest new treatment targets [4].

In conclusion, TMEM185A shows potential significance in cancer-related biological processes, especially in breast, urinary bladder, and ovarian cancers. Its identification as a neoantigen and part of gene signatures in different cancers highlights its potential as a therapeutic target and prognostic marker, although more in-depth functional studies, potentially using gene knockout (KO) or conditional knockout (CKO) mouse models, are needed to fully understand its role in these disease conditions.